This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Find out solutions to mitigate the impact from clinicalsupply chain risk and discover how to improve dynamic drug supply forecasting strategies. Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk.
Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceuticaldevelopment expertise. Sairiyo is currently focused on advancing the clinicaldevelopment of Cepharanthine to treat rare cancer diseases.
Under the agreement, during the option period, Molecular Partners will conduct Phase 1 clinical trials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinical trials, with Molecular Partners as sponsor of these trials.
Also, we should not rely solely on pharmaceuticals to address the root causes of systemic health issues. These drugs could drastically lower rates of many life-affecting diseases and ailments, such as diabetes, cardiovascular disease and other metabolic disorders and contribute to improving millions of lives.
But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
“I find it very exciting as well as surprising that the FDA is putting their foot on the gas in terms of helping roll out AI internally within the agency, because it actually aligns quite nicely with the adoption speed that were seeing within the pharmaceutical manufacturing side of the table,” Feiger said.
I worked to continually grow my expertise, responsibility, and leadership before ultimately taking on my current role as Senior Vice President and Global Head of Clinical Operations at BeOne. My proudest achievement is my leadership journey building legacy organisations, processes and tools in clinical operations.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content